Generic Name and Formulations:
Mesalamine 0.375g; ext-rel caps; contains phenylalanine 0.56mg/cap.
Bausch Health Companies Inc.
Indications for APRISO:
Maintenance of remission of ulcerative colitis (UC) in adults.
≥18yrs: 1.5g once daily in the AM.
<18yrs: not established.
Sulfasalazine allergy. Renal dysfunction or history of renal disease; assess renal function at the beginning and periodically during treatment. Hepatic impairment. Elderly (monitor CBCs). Pregnancy (Cat.B). Nursing mothers.
Do not co-administer with antacids.
Headache, nausea, diarrhea, upper abdominal pain, nasopharyngitis, flu-like symptoms, sinusitis; renal impairment, mesalamine-induced acute intolerance syndrome (eg, cramping, abdominal pain, bloody diarrhea, fever, headache, rash); discontinue if occurs.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age